Venous Thromboembolism in Patients Diagnosed With Lung Cancer

Abstract

Efforts to assess thrombotic risk in patients with lung cancer may improve therapeutic and preventive strategies in the future, with final goal to minimize the burden and consequences of thrombotic events in patients with lung cancer.

Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma

“…NSCLC patients with adenocarcinoma and advanced cancer may more frequently develop VTE (32). When administrating medical treatment, both specific anti neoplastic agents and supportive care agents (particular bevacizumab) may have increased the risk (32,35). Lung cancer patients who suffer from thromboembolism events have higher mortality rates, more economic costs and greater disability upon discharge than those without such complications (33).…”

“…On one hand, some biomarkers and predictors of thromboembolism have been investigated, with D-dimer (32,36) and EGFR mutation being regarded as the most promising and reproducible ones, which may help to early identify thromboembolism events in clinical practice. Furthermore, low-molecular-weight heparins (LMWH) and direct oral anticoagulants have been used for treatment of the established thromboembolism (35,37). Effective prophylaxis and proper treatment of VTE play an important role in cancer management for the benefits of reducing morbidity and mortality, and improving quality of life (38).…”

A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS–Cancer-Associated Thrombosis Study

“…Venous thromboembolism (VTE) significantly increases the mortality and deteriorates the quality of life for cancer patients [1][2][3]. The overall incidence of symptomatic VTE in ambulatory patients with breast, colon, lung, or ovarian cancer is approximately 3% [4][5][6][7]. However, the risk of VTE increases by sixfold in outpatients on chemotherapy and in patients with advanced disease [8][9][10].…”

Middle Molecular Weight Heparinyl Amino Acid Derivatives (MHADs) Function as Indirect Radical Scavengers <i>in Vitro</i>

“…To resolve this, we have synthesized MHADs to reduce the hemorrhage activity of HE with beneficial effects. Recently, low-molecular-weight heparins (LMWHs) are being used as anticoagulants and these are much safer than conventional HE [28]- [30]. In this study, we did not only try to decrease the molecular weight of HE, but also conjugate amino acids to reduce its high hemorrhagic tendency.…”